Novo Nordisk's Weight-Loss Drugs Boost Danish Economy Amid Local Health Challenges

Despite Novo Nordisk's economic success, Kalundborg faces high rates of childhood obesity near its production hub.

Novo Nordisk, Europe's largest company by market cap, has significantly boosted Denmark's economy with its popular drugs Ozempic and Wegovy.
Kalundborg, home to Novo Nordisk's major manufacturing plant, struggles with one of Denmark's highest rates of overweight children.
The company's success has raised concerns of 'Nokia risk,' where Denmark might become overly reliant on its pharmaceutical sector.
Novo Nordisk's origins trace back to a non-profit foundation established to benefit society, controlling 77% of the company's voting shares.
While Novo Nordisk's drugs are praised globally, the company faces criticism over high prices, particularly in the U.S. market.